A5057612666- Liver Disease Diagnosis and Treatment
- Liver Disease and Transplantation
- Organ Transplantation Techniques and Outcomes
- Hepatitis C virus research
- Liver Diseases and Immunity
- Renal Transplantation Outcomes and Treatments
- Hepatitis B Virus Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Transplantation: Methods and Outcomes
- Viral-associated cancers and disorders
- Polyomavirus and related diseases
- Cardiovascular Function and Risk Factors
- Nutrition and Health in Aging
- Bariatric Surgery and Outcomes
- Alcohol Consumption and Health Effects
- Gallbladder and Bile Duct Disorders
- Hepatitis Viruses Studies and Epidemiology
- Clinical Nutrition and Gastroenterology
- Hepatocellular Carcinoma Treatment and Prognosis
- Diet, Metabolism, and Disease
- Pancreatitis Pathology and Treatment
- Pediatric Hepatobiliary Diseases and Treatments
- Cytomegalovirus and herpesvirus research
- Metabolism and Genetic Disorders
- Diet and metabolism studies
Mayo Clinic in Arizona
2016-2025
Mayo Clinic
2016-2025
WinnMed
2015-2025
Vanderbilt University Medical Center
2021
Mayo Clinic in Florida
2010-2018
Temple College
2015
Texas A&M University
2015
University of Pennsylvania
2015
Columbia University
2015
The University of Melbourne
2015
There are no effective and safe treatments for chronic hepatitis C virus (HCV) infection of patients who have advanced liver disease.In this phase 2, open-label study, we assessed treatment with the NS5A inhibitor ledipasvir, nucleotide polymerase sofosbuvir, ribavirin in infected HCV genotypes 1 or 4. Cohort A enrolled cirrhosis moderate severe hepatic impairment had not undergone transplantation. B transplantation: those without cirrhosis; mild, moderate, impairment; fibrosing cholestatic...
Cardiac and cerebral vascular diseases are leading causes of morbidity death in solid organ transplant recipients. Immunosuppressant drugs associated with dyslipidemia, hypertension, hyperglycemia, which along obesity the main features metabolic syndrome. In nontransplant population, syndrome is increased risk for major complications. We postulated that common post-liver transplantation plays a significant role to cardiac cerebrovascular events. Our Multi-Organ Transplant Program database...
Cirrhotic cardiomyopathy (CCM) is cardiac dysfunction in patients with end-stage liver disease the absence of prior heart disease. First defined 2005 during World Congress Gastroenterology, CCM criteria consisted echocardiographic parameters to identify subclinical overt structural abnormalities. Significant advancements cardiovascular imaging over past 14 years, including integration myocardial deformation into routine clinical practice dysfunction, have rendered obsolete. Therefore, new...
Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. Our aim was to analyze the effectiveness of a multidisciplinary protocol for obese patients requiring LT, including noninvasive pretransplant weight loss program, combined LT plus sleeve gastrectomy (SG) who failed lose prior LT. Since 2006, all referred with BMI > 35 were enrolled. There 37 achieved underwent alone, 7 SG. In those received gain seen in 21/34, post-LT diabetes...
Nonalcoholic fatty liver disease (NAFLD) includes a wide spectrum of manifestations ranging from nonalcoholic (NAFL) to steatohepatitis (NASH), fibrosis and eventually cirrhosis. The prevalence NAFLD has been shown be increasing over time; however, the NASH cirrhosis advanced time not well studied. Estimate changes in NAFLD-associated among adults United States.National Health Nutrition Examination Survey (NHANES) data obtained during periods 1999-2002 2009-2012 were analyzed estimate...
The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence obesity syndrome (MS), define cumulative incidence CVD, characterize risk factors associated with these comorbidities LT. A retrospective review 455 consecutive LT recipients from 1999 2004 an 8‐ 12‐year follow‐up was performed. Obesity increased 23.8% (4 months) 40.8% (3 years) Increase in body mass index predicted MS at 1...
The impact of obesity on outcomes following liver transplantation has been difficult to determine, in part due the confounding effects ascites BMI. We evaluated pretransplant recipient using NIDDK Liver Transplantation Database. Pretransplant BMI, corrected for ascites, was categorized as underweight (BMI <18 kg/m(2)), normal weight 18-25 overweight 25.1-30 Class I obese 30.1-35 II 35.1-40 kg/m(2)) and III >40 kg/m(2)). Primary were patient graft survival. Secondary included days hospital...
Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along minimal adverse events non–liver transplant (LT) patients hepatitis C virus (HCV) genotype 1 infection. This is the first multicenter report on efficacy, safety, tolerability of this LT recipients. A total 123 (76% male, 74% white, 60% 1a, 30% METAVIR F3‐F4, 4% decompensation, 11% cholestatic...
In industrialized countries, over-the-counter dietary supplements have become popular in preventing and treating an expanding list of medical conditions. Although most commercially available not been rigorously tested for safety efficacy, they found enlarging market because are considered natural. Oral containing green tea extract marketed as effective weight loss to prevent cure some solid tumors. there is little scientific evidence the effectiveness extracts improve quality health regular...
Obesity is increasingly common before and after liver transplantation (LT), yet optimal management remains unclear. The aim of this study was to analyze the long-term outcomes for obese patients undergoing LT, including a noninvasive weight loss program combined LT sleeve gastrectomy (SG). Since 2006, all referred with body mass index (BMI) ≥35 kg/m2 were enrolled. Patients who achieved (BMI <35) underwent alone, those did not simultaneous + SG. Analysis ≥3 years posttransplant performed....
To analyze the frequency and trend of liver transplantation (LT) for nonalcoholic steatohepatitis (NASH) cirrhosis in young adults aged 18 to 40 years assess post-LT outcomes this age group.NASH is currently fastest-growing indication LT US adults. It believed that NASH a rare among adults.Using United Network Organ Sharing database, we performed retrospective cohort analysis all LTs between 2002 2012. Incidence rate ratio was calculated each indication.A total 5157 underwent over study...
Sarcopenia and frailty are commonly encountered in patients with end‐stage liver disease associated adverse clinical outcomes, including decompensation wait‐list mortality. The impact of these entities differing etiologies has not been elucidated. We aim to ascertain the change their prevalence over time on wait list determine hospitalization, delisting, survival, specifically for nonalcoholic steatohepatitis (NASH) alcoholic (ALD). Adult who were evaluated first transplant from 2014 2016 a...
Summary Background Lipotoxicity leading to excessive caspase‐mediated apoptosis and inflammation is believed drive liver damage in NAFLD. Emricasan a pan‐caspase inhibitor that decreased serum ALT apoptotic inflammatory markers subjects with chronic hepatitis. Aims To assess whether 28 days of emricasan would reduce elevated levels ALT, AST, cleaved cytokeratin‐18, full‐length caspase 3/7 NAFLD raised aminotransferases. Methods Double‐blind, placebo‐controlled, office‐practice study assessed...
Hepatic steatosis is strongly associated with cardiovascular disease in the general population. Whether recurrent or de novo, it can occur allograft, but impact on survival and long-term clinical outcomes remains unclear. In this study, we aim to determine both frequency of allograft posttransplant outcomes.A retrospective review 588 adult liver transplant (LT) recipients (1999-2006) was performed. Cox regression analysis (time-dependent) used evaluate differences time post-LT, patient...